SAN DIEGO, November 4, 2013 /PRNewswire/ – Profil Institute for Clinical Research, Inc., a company providing science-driven early phase diabetes and obesity clinical research, announced today the appointment of Dan Bradbury, Managing Member of BioBrit, LLC and former Amylin Pharmaceutical CEO, to its Board of Directors. Mr. Bradbury joins Profil Institute’s current Board Directors Dr. John Amatruda, a pharmaceutical research executive and former Senior Vice President and Head of Diabetes and Obesity at Merck Research Laboratories; Dr. Jerrold Olefsky, Professor of Medicine at the University of California, San Diego (UCSD) Division of Endocrinology and Metabolism and the Associate Dean of Scientific Affairs for the UCSD School of Medicine; Dr. Linda Morrow, Profil Institute’s COO; and Dr. Marcus Hompesch, Profil Institute’s President and CEO.
“We are extremely pleased to welcome Dan to our board of directors. We are pleased to have a person of his business acumen and relevant experience join our Board of Directors,” said Dr. Hompesch. “His knowledge, insight and years of leadership experience at global pharmaceutical companies will be invaluable in helping to further shape the company’s strategic course.”
“Profil Institute inhabits a unique space in today’s clinical research industry as a therapeutically focused CRO capable of providing competent and robust guidance on all aspects of early clinical development strategy and execution, and as an innovator of new methodologies to generate more meaningful data for early phase studies,” said Mr. Bradbury. “Profil Institute is a growth story that I’m excited to be a part of and am pleased to join at this time of strategic decisions for the continued expansion for the company.”
Mr. Bradbury is a life sciences executive with over 30 years of experience creating and implementing strategies that transform businesses and bring novel medicines to market. He is currently Managing Member of BioBrit, LLC, a life sciences consulting and investment firm. Prior to that, Mr. Bradbury served as Amylin Pharmaceuticals’ President, Chief Executive Officer and Director from 2007 until its acquisition by Bristol-Myers Squibb Company in 2012. Amylin is a biopharmaceutical company focused on metabolic diseases and based in San Diego. During Mr. Bradbury’s 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. Prior to joining Amylin, Mr. Bradbury worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals.
Mr. Bradbury serves on the Board of Directors of Corcept Therapeutics (NASDAQ: CORT), Geron Corporation (NASDAQ: GERN), Illumina, Inc. (NASDAQ: ILMN), BioMed Realty (NYSE: BMR), Biocon Limited (NSE: BIOCON), Castle Biosciences, Inc. (Private), DiaVacs (Private) and Microdermis, Inc. (Private). He also serves on the Board of Trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, and the BioMed Ventures Advisory Committee. In addition to his Board positions, Mr. Bradbury serves on the University of California San Diego’s Rady School of Management’s Advisory Council and the University of Miami’s Innovation Corporate Advisory Council.
About Profil® Institute for Clinical Research, Inc.
Profil Institute is a Center of Excellence performing early phase clinical research of drugs and devices for diabetes and obesity and providing scientific support for metabolic drug target profiling, clinical development planning, publication activities and the establishment of scientific advisory boards. The company’s scientific expertise, metabolic clinical research methodologies, and automated glucose clamp technology enable Profil Institute to execute highly complex studies and have led Profil Institute to be a highly regarded clinical research institute for early phase metabolic drug studies. Profil Institute has been involved with every clinically relevant drug class in diabetes and in more than 200 clinical studies since the company’s inception in 2004. For more information, visit www.profilinstitute.com.
For further information, please contact: